Inc. therapeutic for ovarian cancer and other cancers announces first data for his novel ImmunoGen,

Current article ratings:
Patients / public:5 (1 votes)healthcare Prof:
ImmunoGen, Inc. (NASDAQ: IMGN), a biotechnology company, antibody developed payload (TAP), based on its know-how and technology antibodies specifically targeted anti-cancer products announced today the coverage of the first data on the company's IMGN853 candidate for the treatment of ovarian cancer and other types of solid tumors. The presentations are at the 102nd Annual meeting of the American Association occurs for cancer research (AACR) in Orlando FL.

IMGN853 to selectively target and kill cancer cells expressing bring folate receptor 1 (FOLR1). This objective is over expressed on most cases of ovarian cancer and other cancers including types of non-small cell lung cancers. IMGN853 found that tumors are highly effective against human ovarian cancer in preclinical testing. The AACR 2011 Program Committee recognized the abstract on the IMGN853 in vivo preclinical findings as points below the top 2% of abstracts for poster presentations.

IMGN853 is compound, meaning that there is a tap from a tumor-targeting antibodies with one ImmunoGen's highly effective cell-killing agent one engineered connected linker. Antibody compound specifically used TAP on cancer cells to targets, and the cell-killing agent is used for the destruction of these cells.

"We have ongoing research, continue to our product to improve development skills as well as our product pipeline, and IMGN853 is several technological innovations, we have made in recent years," commented John Lambert, PhD., Executive Vice President and Chief Scientific Officer. "For example, developed we the IMGN853 linker used, to not only stable as all our linker, but also that have occurred with wide fight of the resistance against, very difficult to treat certain types of cancer." "This increases the activity of the IMGN853 in preclinical tests continue."

Dr. Lambert went on: "We also constantly refine the criteria we use to generate and select antibody connections for use in cock as we identify opportunities, therapeutic activity to improve each connection." "We evaluate antibodies in the selection used in IMGN853 of 100 FOLR1 targeting."

Among the findings reported data shows:

-The destination for IMGN853 - FOLR1 - robust expressed on most ovarian cancer as well as on certain non-small cell cell lung cancers and other cancers. This is based methods scientists (abstract # 3617); on objective quantification developed by ImmunoGen

-The design of the IMGN853 has been optimized for your destination - both in its antibody component of novel of linker used, attach to the highly effective payload to the antibodies and controlling its release within a cancer cell (abstract # 4576); and

-IMGN853 candidate is a very active against human ovarian tumours in preclinical tests (abstract # 1760). This was as a highly rated poster presentation of the program Committee 2011 by the AACR set.

About IMGN853

IMGN853 is in development for the treatment of ovarian cancer and other cancers, the folate receptor 1 (FOLR1) over-express. This TAP connection consists of a FOLR1-targeting antibodies with the company's proprietary DM4 cancer cell-killing agent associated with a new linker of ImmunoGen developed for the control of cancer is with wide resistance. IMGN853 it was found that highly effective against tumors ovarian cancer in preclinical tests and is on the way IND in for delivery early 2012.

Source:
ImmunoGen, Inc.